

Scleroderma-overlap syndromes: capillaroscopy, laboratory, and clinical manifestations and follow-up compared to scleroderma patients

Saeedeh Shenavandeh , Zahra Azariyon, Mohammad Ali Nazarinia 

Division of Rheumatology, Department of Internal Medicine, Shiraz University of Medical Science, Iran

Abstract

Introduction: Overlap syndrome (OS) is a group of systemic connective tissue diseases (CTDs) that meet the criteria of two or more CTDs. In this study, we evaluated clinical, laboratory, and capillaroscopic manifestations of patients with scleroderma OS (SSc-OS) and its subgroups and follow-up progression compared to patients with limited SSc (LcSSc).

Material and methods: In a 10-year cross-sectional study, we evaluated 135 adult patients (70 with SSc-OS and 65 with LcSSc) with the same skin score for their baseline and follow-up clinical, laboratory, high-resolution chest tomography (HRCT), echocardiography, and nailfold capillaroscopy data and compared them.

Results: Of the 135 patients, 70 had SSc-OS, including 45 (64.3%) cases of SSc-SS (Sjögren's syndrome), 11 (15.7%) of SSc-RA (rheumatoid arthritis), 9 (12.9%) of SSc-myositis and 5 (1.7%) of SSc-SLE (systemic lupus erythematosus), and 65 had LcSSc. Lung and heart involvement and pulmonary arterial hypertension (PAH) did not differ between the two groups ($p > 0.05$). Musculoskeletal involvement and non-specific pattern of capillaroscopy were higher ($p = 0.035$ and $p = 0.001$), and digital ulcer (DU) and scleroderma patterns of capillaroscopy were lower in the SSc-OS group ($p = 0.000$).

No significant relationship was found between capillaroscopic patterns and organ involvement in the two groups (p -value > 0.05). In the follow-up (3.71 \pm 2.63 years), new DU and progression of lung involvement ($p = 0.002$) and the progression in capillaroscopic patterns was lower in SSc-OS ($p = 0.000$). In the follow-up, new DU was not seen in the SSc-OS, with lower progression of lung involvement, skin score, and capillary damage.

Conclusions: In SSc-OS patients, the most common subgroup was SSc-SS. Scleroderma OS was associated with lower major organ involvement and capillaroscopy progression than LcSSc. Major organ involvement in patients with SSc-OS was significantly lower than in LcSSc patients. In the follow-up, new DU was not seen in the SSc-OS with lower progression of lung involvement, skin score, and capillary damage.

Key words: scleroderma-overlap, scleroderma, nailfold capillaroscopy, interstitial lung disease, pulmonary arterial hypertension.

Introduction

Overlap syndromes (OS) are systemic autoimmune diseases in which diagnostic criteria of at least two or more connective tissue diseases (CTDs) are fulfilled [1].

The most usual associations include systemic sclerosis (SSc), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis (DM) or polymyositis (PM), and primary Sjögren's syndrome (pSS) [1]. Synovitis and myositis were reported to be more common in

Address for correspondence:

Saeedeh Shenavandeh, Shiraz University of Medical Science, Department of Internal Medicine, Division of Rheumatology, Namazee Hospital, Shiraz, Iran, PO Box: 71345-1414, e-mail: shenavandehs@gmail.com

Submitted: 28.02.2023; Accepted: 20.11.2023

patients in future studies. The fourth limitation of our study was not assessing other SSc-related autoantibodies (i.e. anti-RNA polymerase III, anti-Pm/Scl or anti-fibrillarin).

Therefore, the need for studies on a larger number of patients with longer duration and other OS groups is recommended as it seems that the presence of overlap manifestations makes the major organ manifestations less severe with a better follow-up progression.

Conclusions

In SSc-OS patients, the most common subgroup was SSc-pSS. The DU, cardiopulmonary, GI involvement, and PAH in patients with SSc-OS were significantly lower than in the LcSSc patients. Musculoskeletal involvement such as arthritis was more commonly seen in SSc-OS patients, especially in the SSc-RA subgroup. The progression of skin score was significantly lower in the SSc-OS patients; also, non-specific patterns in capillaroscopy were significantly higher than in the LcSSc patients, and the evidence of progression and changes in capillaroscopic patterns was significantly lower in the SSc-OS than the LcSSc group. In follow-up, new DU and the evidence of progression of lung involvement and skin score were significantly lower in the SSc-OS than LcSSc patients.

Acknowledgements

The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran and the Center for Development of Clinical Research of Namazee Hospital and Dr. Nasrin Shokrpour for editorial assistance.

The authors declare no conflict of interest.

This thesis was supported by the Dean of the School of Medicine based on research project number 20306 and sponsored by the Vice Chancellor of Shiraz University of Medical Sciences.

All data and materials of this manuscript are available from the corresponding author on reasonable request.

References

1. Wielosz E, Majdan M, Dryglewska M, Targońska-Stępnia B. Overlap syndromes in systemic sclerosis. *Postepy Dermatol Alergol* 2018; 35: 246–250, DOI: 10.5114/ada.2018.72662.
2. Fairley JL, Hansen D, Proudman S, et al. Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes. *Arthritis Care Res (Hoboken)* 2021; 73: 732–741, DOI: 10.1002/acr.24167.
3. Iaccarino L, Gatto M, Bettio S, et al. Overlap connective tissue disease syndromes. *Autoimmun Rev* 2013; 12: 363–373, DOI: 10.1016/j.autrev.2012.06.004.
4. Shenavandeh S, Habibi S, Habibi Y, Nazarinia M. Mechanic hands: clinical and capillaroscopy manifestations of patients with connective tissue diseases presented with and without mechanic hands. *Clin Rheumatol* 2019; 38: 2309–2318, DOI: 10.1007/s10067-018-04422-z.
5. Quinlivan A, Ross L, Proudman S. Systemic sclerosis: Advances towards stratified medicine. *Best Pract Res Clin Rheumatol* 2020; 34: 101469, DOI: 10.1016/j.berh.2019.101469.
6. van Roon AM, Huisman CC, van Roon AM, et al. Abnormal Nailfold Capillaroscopy Is Common in Patients with Connective Tissue Disease and Associated with Abnormal Pulmonary Function Tests. *J Rheumatol* 2019; 46: 1109–1116, DOI: 10.3899/jrheum.180615.
7. Markusse IM, Meijis J, de Boer B, et al. Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. *Rheumatology (Oxford)* 2017; 56: 1081–1088, DOI: 10.1093/rheumatology/kew402.
8. Smith V, Ricciari V, Pizzorni C, et al. Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis. *J Rheumatol* 2013; 40: 2023–2028, DOI: 10.3899/jrheum.130528.
9. Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM, et al. Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon. *Rheumatol Int* 2012; 32: 3039–3045, DOI: 10.1007/s00296-011-2109-2.
10. Nagy G, Czirják L, Kumánovics G. Patients with Systemic Sclerosis with and without Overlap Syndrome Show Similar Microvascular Abnormalities. *Diagnostics (Basel, Switzerland)* 2021; 11: 1606, DOI: 10.3390/diagnostics11091606.
11. Sharma S, Kumar U. Scleroderma overlap syndromes. *Int J Rheum Dis* 2016; 19: 831–833, DOI: 10.1111/1756-185X.13011.
12. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2013; 72: 1747–1755, DOI: 10.1136/annrheumdis-2013-204424.
13. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). *New Engl J Med* 1975; 292: 403–407, DOI: 1056/NEJM197502202920807.
14. Aydın SZ, Castillo-Gallego C, Nam J, et al. The new ACR/EULAR criteria for rheumatoid arthritis can identify patients with same disease activity but less damage by ultrasound. *Eur J Rheumatol* 2017; 4: 118–121, DOI: 10.5152/eurjrheum.2017.160091.
15. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol* 2019; 71: 1400–1412, DOI: 10.1002/art.40930.
16. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis Rheumatol* 2017; 69: 35–45, DOI: 10.1002/art.39859.